Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors
A Phase II Study of Serplulimab Plus Chemoradiotherapy as Adjuvant Treatment for Postoperative Cervical Cancer with Multiple Risk Factors
Trial Details
- NCT ID
- NCT06727617
- Phase
- PHASE2
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Cancer Type
- Cervical Cancer
- Interventions
- Serplulimab
- Chemotherapy
- radiotherapy
- Locations (sample)
- Tianjin, Tianjin Municipality, China|39.14222,117.17667
Key Eligibility Criteria
- Voluntarily participate in the clinical study: Fully understand and be informed about the study, and sign the informed consent form (ICF); willing …
- Female aged ≥18 years and ≤65 years at the time of signing the ICF.
- ECOG PS score of 0 or 1.
- Positive PD-L1 status (CPS ≥1).
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Cervical Cancer Trials on Trialify →